Which has preferable valuation and earnings, TET or VCT?

Victrex has higher revenue and earnings than Treatt. Victrex is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Treatt £128.29M 1.40 £11.22M £7.22 42.04 Victrex £296.40M 1.76 £30.80M -£22.40 N/A

Is TET or VCT more profitable?

Treatt has a net margin of 3.40% compared to Victrex's net margin of -6.70%. Treatt's return on equity of 3.22% beat Victrex's return on equity. Company Net Margins Return on Equity Return on Assets Treatt 3.40% 3.22% 6.72% Victrex -6.70% -4.95% 6.59%

Do analysts rate SCPA or TET?

Treatt has a consensus target price of GBX 248.33, suggesting a potential downside of 18.18%. Given Scapa Group's higher probable upside, analysts clearly believe Scapa Group is more favorable than Treatt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scapa Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Treatt 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, SCPA or TET?

Treatt has lower revenue, but higher earnings than Scapa Group. Scapa Group is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scapa Group £281.80M 0.00 N/A -£29.30 N/A Treatt £128.29M 1.40 £11.22M £7.22 42.04

Is SCPA or TET more profitable?

Treatt has a net margin of 3.40% compared to Scapa Group's net margin of 0.00%. Treatt's return on equity of 3.22% beat Scapa Group's return on equity. Company Net Margins Return on Equity Return on Assets Scapa Group N/A N/A N/A Treatt 3.40% 3.22% 6.72%

Which has preferable earnings & valuation, ESNT or TET?

Treatt has lower revenue, but higher earnings than Essentra. Treatt is trading at a lower price-to-earnings ratio than Essentra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Essentra £302M 0.76 £3.50M £0.70 117.71 Treatt £128.29M 1.40 £11.22M £7.22 42.04

Is ESNT or TET more profitable?

Treatt has a net margin of 3.40% compared to Essentra's net margin of 0.70%. Treatt's return on equity of 3.22% beat Essentra's return on equity. Company Net Margins Return on Equity Return on Assets Essentra 0.70% 0.79% 1.74% Treatt 3.40% 3.22% 6.72%

Which has stronger valuation and earnings, TET or ZTF?

Treatt has higher earnings, but lower revenue than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Treatt £128.29M 1.40 £11.22M £7.22 42.04 Zotefoams £158.49M 1.29 £9.80M £44.87 9.29

Is TET or ZTF more profitable?

Zotefoams has a net margin of 14.28% compared to Treatt's net margin of 3.40%. Zotefoams' return on equity of 18.25% beat Treatt's return on equity. Company Net Margins Return on Equity Return on Assets Treatt 3.40% 3.22% 6.72% Zotefoams 14.28% 18.25% 5.48%

Which has higher valuation & earnings, TET or SYNT?

Treatt has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Treatt £128.29M 1.40 £11.22M £7.22 42.04 Synthomer £1.74B 0.08 -£82.04M -£96.00 N/A

Is TET or SYNT more profitable?

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -9.03%. Treatt's return on equity of 3.22% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Treatt 3.40% 3.22% 6.72% Synthomer -9.03% -16.66% -0.28%

Treatt (TET) Competitors

GBX 303.50 0.00 (0.00%)

As of 12:27 PM Eastern

Compare

TET vs. VCT, SCPA, ESNT, ZTF, and SYNT

Should you buy Treatt stock or one of its competitors? MarketBeat compares Treatt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Treatt include Victrex (VCT), Scapa Group (SCPA), Essentra (ESNT), Zotefoams (ZTF), and Synthomer (SYNT). These companies are all part of the "specialty chemicals" industry.

How does Treatt compare to Victrex?

Treatt (LON:TET) and Victrex (LON:VCT) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Treatt has a net margin of 3.40% compared to Victrex's net margin of -6.70%. Treatt's return on equity of 3.22% beat Victrex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treatt	3.40%	3.22%	6.72%
Victrex	-6.70%	-4.95%	6.59%

Treatt pays an annual dividend of GBX 5.60 per share and has a dividend yield of 1.8%. Victrex pays an annual dividend of GBX 59.56 per share and has a dividend yield of 9.9%. Treatt pays out 77.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Victrex pays out -265.9% of its earnings in the form of a dividend. Victrex is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Victrex had 1 more articles in the media than Treatt. MarketBeat recorded 1 mentions for Victrex and 0 mentions for Treatt. Victrex's average media sentiment score of 0.72 beat Treatt's score of 0.25 indicating that Victrex is being referred to more favorably in the news media.

Company	Overall Sentiment
Treatt	Neutral
Victrex	Positive

Treatt has a beta of 0.907, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Victrex has a beta of 0.756, suggesting that its stock price is 24% less volatile than the broader market.

Treatt currently has a consensus price target of GBX 248.33, indicating a potential downside of 18.18%. Victrex has a consensus price target of GBX 662.86, indicating a potential upside of 10.66%. Given Victrex's higher possible upside, analysts clearly believe Victrex is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Victrex	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

17.5% of Treatt shares are held by institutional investors. Comparatively, 75.5% of Victrex shares are held by institutional investors. 4.1% of Treatt shares are held by insiders. Comparatively, 4.2% of Victrex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Victrex has higher revenue and earnings than Treatt. Victrex is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treatt	£128.29M	1.40	£11.22M	£7.22	42.04
Victrex	£296.40M	1.76	£30.80M	-£22.40	N/A

Summary

Victrex beats Treatt on 11 of the 18 factors compared between the two stocks.

How does Treatt compare to Scapa Group?

Scapa Group (LON:SCPA) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Treatt has a net margin of 3.40% compared to Scapa Group's net margin of 0.00%. Treatt's return on equity of 3.22% beat Scapa Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scapa Group	N/A	N/A	N/A
Treatt	3.40%	3.22%	6.72%

Treatt has lower revenue, but higher earnings than Scapa Group. Scapa Group is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scapa Group	£281.80M	0.00	N/A	-£29.30	N/A
Treatt	£128.29M	1.40	£11.22M	£7.22	42.04

17.5% of Treatt shares are held by institutional investors. 4.1% of Treatt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Treatt has a consensus target price of GBX 248.33, suggesting a potential downside of 18.18%. Given Scapa Group's higher probable upside, analysts clearly believe Scapa Group is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scapa Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Treatt's average media sentiment score of 0.25 beat Scapa Group's score of 0.00 indicating that Treatt is being referred to more favorably in the news media.

Company	Overall Sentiment
Scapa Group	Neutral
Treatt	Neutral

Summary

Treatt beats Scapa Group on 10 of the 12 factors compared between the two stocks.

How does Treatt compare to Essentra?

Essentra (LON:ESNT) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Treatt has a net margin of 3.40% compared to Essentra's net margin of 0.70%. Treatt's return on equity of 3.22% beat Essentra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Essentra	0.70%	0.79%	1.74%
Treatt	3.40%	3.22%	6.72%

69.5% of Essentra shares are owned by institutional investors. Comparatively, 17.5% of Treatt shares are owned by institutional investors. 0.5% of Essentra shares are owned by insiders. Comparatively, 4.1% of Treatt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Essentra presently has a consensus price target of GBX 150, suggesting a potential upside of 82.04%. Treatt has a consensus price target of GBX 248.33, suggesting a potential downside of 18.18%. Given Essentra's stronger consensus rating and higher probable upside, analysts clearly believe Essentra is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Essentra	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Treatt's average media sentiment score of 0.25 beat Essentra's score of 0.00 indicating that Treatt is being referred to more favorably in the news media.

Company	Overall Sentiment
Essentra	Neutral
Treatt	Neutral

Treatt has lower revenue, but higher earnings than Essentra. Treatt is trading at a lower price-to-earnings ratio than Essentra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Essentra	£302M	0.76	£3.50M	£0.70	117.71
Treatt	£128.29M	1.40	£11.22M	£7.22	42.04

Essentra pays an annual dividend of GBX 2.35 per share and has a dividend yield of 2.9%. Treatt pays an annual dividend of GBX 5.60 per share and has a dividend yield of 1.8%. Essentra pays out 335.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Treatt pays out 77.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Essentra has a beta of 0.822, meaning that its share price is 18% less volatile than the broader market. Comparatively, Treatt has a beta of 0.907, meaning that its share price is 9% less volatile than the broader market.

Summary

Treatt beats Essentra on 10 of the 17 factors compared between the two stocks.

How does Treatt compare to Zotefoams?

Treatt (LON:TET) and Zotefoams (LON:ZTF) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Treatt pays an annual dividend of GBX 5.60 per share and has a dividend yield of 1.8%. Zotefoams pays an annual dividend of GBX 7.60 per share and has a dividend yield of 1.8%. Treatt pays out 77.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zotefoams pays out 16.9% of its earnings in the form of a dividend.

Treatt currently has a consensus price target of GBX 248.33, suggesting a potential downside of 18.18%. Zotefoams has a consensus price target of GBX 605, suggesting a potential upside of 45.08%. Given Zotefoams' stronger consensus rating and higher possible upside, analysts plainly believe Zotefoams is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zotefoams	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

17.5% of Treatt shares are owned by institutional investors. Comparatively, 29.6% of Zotefoams shares are owned by institutional investors. 4.1% of Treatt shares are owned by company insiders. Comparatively, 4.5% of Zotefoams shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Treatt has a beta of 0.907, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Zotefoams has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Zotefoams has a net margin of 14.28% compared to Treatt's net margin of 3.40%. Zotefoams' return on equity of 18.25% beat Treatt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treatt	3.40%	3.22%	6.72%
Zotefoams	14.28%	18.25%	5.48%

Treatt has higher earnings, but lower revenue than Zotefoams. Zotefoams is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treatt	£128.29M	1.40	£11.22M	£7.22	42.04
Zotefoams	£158.49M	1.29	£9.80M	£44.87	9.29

In the previous week, Zotefoams had 1 more articles in the media than Treatt. MarketBeat recorded 1 mentions for Zotefoams and 0 mentions for Treatt. Treatt's average media sentiment score of 0.25 beat Zotefoams' score of 0.00 indicating that Treatt is being referred to more favorably in the media.

Company	Overall Sentiment
Treatt	Neutral
Zotefoams	Neutral

Summary

Zotefoams beats Treatt on 12 of the 18 factors compared between the two stocks.

How does Treatt compare to Synthomer?

Treatt (LON:TET) and Synthomer (LON:SYNT) are both small-cap basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

17.5% of Treatt shares are held by institutional investors. Comparatively, 19.7% of Synthomer shares are held by institutional investors. 4.1% of Treatt shares are held by insiders. Comparatively, 5.0% of Synthomer shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Synthomer had 5 more articles in the media than Treatt. MarketBeat recorded 5 mentions for Synthomer and 0 mentions for Treatt. Synthomer's average media sentiment score of 0.38 beat Treatt's score of 0.25 indicating that Synthomer is being referred to more favorably in the news media.

Company	Overall Sentiment
Treatt	Neutral
Synthomer	Neutral

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -9.03%. Treatt's return on equity of 3.22% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treatt	3.40%	3.22%	6.72%
Synthomer	-9.03%	-16.66%	-0.28%

Treatt presently has a consensus target price of GBX 248.33, suggesting a potential downside of 18.18%. Synthomer has a consensus target price of GBX 86.75, suggesting a potential downside of 1.87%. Given Synthomer's higher probable upside, analysts clearly believe Synthomer is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Treatt has a beta of 0.907, indicating that its share price is 9% less volatile than the broader market. Comparatively, Synthomer has a beta of 1.012, indicating that its share price is 1% more volatile than the broader market.

Treatt has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treatt	£128.29M	1.40	£11.22M	£7.22	42.04
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A

Summary

Treatt beats Synthomer on 9 of the 16 factors compared between the two stocks.

Get Treatt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TET vs. The Competition

Export

Metric	Treatt	Specialty Chemicals Industry	Materials Sector	LON Exchange
Market Cap	£179.17M	£8.86B	£4.73B	£2.78B
Dividend Yield	1.85%	3.41%	5.00%	6.16%
P/E Ratio	42.04	15.60	22.29	365.72
Price / Sales	1.40	119.08	5,908.37	86,253.69
Price / Cash	165.43	19.57	27.05	27.85
Price / Book	1.30	3.36	8.84	7.92
Net Income	£11.22M	£213.62M	£157.26M	£5.89B
7 Day Performance	N/A	0.00%	-3.46%	-0.87%
1 Month Performance	0.82%	-0.89%	-4.15%	-0.76%
1 Year Performance	18.32%	25.42%	52.00%	70.67%

Treatt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TET Treatt	0.7505 of 5 stars	GBX 303.50 flat	GBX 248.33 -18.2%	+11.0%	£179.17M	£128.29M	42.04	350
VCT Victrex	1.7318 of 5 stars	GBX 617 +0.2%	GBX 662.86 +7.4%	-18.8%	£537.56M	£296.40M	N/A	1,109
SCPA Scapa Group	N/A	N/A	N/A	N/A	£402.98M	£281.80M	N/A	1,461
ESNT Essentra	3.2684 of 5 stars	GBX 82.70 -1.3%	GBX 150 +81.4%	-15.6%	£231.73M	£302M	118.14	350
ZTF Zotefoams	4.0628 of 5 stars	GBX 451.50 +0.9%	GBX 605 +34.0%	+53.0%	£222.06M	£158.49M	10.06	549	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:TET) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Treatt (TET) Competitors